肢端肥大症药物治疗研究进展  

Advancements in pharmacotherapy for acromegaly

作　　者：本刊编辑部 CJEM Editorial Office

机构地区：[1]不详

出　　处：《中华内分泌代谢杂志》2024年第7期616-620,共5页Chinese Journal of Endocrinology and Metabolism

摘　　要：肢端肥大症的治疗主要包括手术、放疗和药物治疗。虽然肢端肥大症的治疗方法在近几十年里取得了显著进展, 但仍有部分患者未能达到生化缓解或临床控制。近期, J Clin Endocrinol Metab就这一问题发表了一篇题为《正在研发中的肢端肥大症新疗法》的综述(Gadelha MR, Gadelha AC, Kasuki L. New treatments for acromegaly in development. J Clin Endocrinol Metab, 2023, 27: dgad568)。该文为开放获取文章, 本文对其进行了中文编译。该综述汇总相关文献, 就目前正在开发中的肢端肥大症的新型药物进行了探讨, 并提出这些新药可能为未来治疗肢端肥大症提供新的选择。Acromegaly treatments mainly include surgery,radiotherapy,and medication.Despite significant progress has been made in the treatment of acromegaly in recent decades,some patients still fail to achieve biochemical remission or clinical control.Recently,J Clin Endocrinol Metab published a review entitled"New therapies for acromegaly in development"(Gadelha MR,Gadelha AC,Kasuki L.J Clin Endocrinol Metab,2023,27:dgad568).This article is open access,and this translation provides an overview of its content in Chinese.The review summarizes relevant literature,discusses novel drugs currently under development for acromegaly,and proposes that these new drugs may offer new options for the treatment of acromegaly in the future.

关 键 词：肢端肥大症 药物治疗 生长激素受体配体 生长激素受体拮抗剂 进展 

分 类 号：R584.11[医药卫生—内分泌]